Top Page
Dai-ichi Life Holdings
(8750)
Dai-ichi Life Holdings (8750) vs. iShares MSCI Japan ETF (EWJ)
Dai-ichi Life Holdings Business Overview & Revenue Model
Dai-ichi Life Holdings Financial Statement Overview
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.48T | 8.80T | 10.49T | 8.41T | 7.86T | 7.57T |
| Gross Profit | 8.48T | 8.80T | 10.49T | 8.41T | 7.86T | 7.57T |
| EBITDA | 502.89B | 611.61B | 565.73B | 395.01B | 591.04B | 589.33B |
| Net Income | 337.54B | 429.61B | 320.76B | 173.74B | 409.35B | 363.78B |
Balance Sheet | ||||||
| Total Assets | 68.59T | 69.59T | 67.54T | 61.58T | 65.88T | 63.59T |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 1.89T | 2.06T | 1.62T | 2.18T | 1.88T |
| Total Debt | 1.14T | 1.19T | 975.29B | 949.67B | 870.38B | 899.77B |
| Total Liabilities | 65.01T | 66.12T | 63.66T | 58.71T | 61.47T | 58.79T |
| Stockholders Equity | 3.58T | 3.47T | 3.88T | 2.66T | 4.41T | 4.81T |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 532.46B | 946.24B | -250.35B | -561.54B | -118.07B |
| Operating Cash Flow | 0.00 | 592.58B | 997.38B | -132.49B | -462.08B | -79.90B |
| Investing Cash Flow | 0.00 | -968.03B | -644.92B | 117.10B | 940.87B | 615.10B |
| Financing Cash Flow | 0.00 | -73.57B | -145.76B | -325.45B | -180.71B | 65.59B |
Dai-ichi Life Holdings Technical Analysis
Dai-ichi Life Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥5.51T | 23.80 | ― | 2.82% | 11.37% | 27.90% | |
72 Outperform | ¥6.37T | 8.98 | 16.44% | 2.59% | 23.01% | 2.59% | |
72 Outperform | ¥2.26T | 5.30 | 20.02% | 2.63% | 23.96% | 179.16% | |
72 Outperform | ¥1.76T | 11.58 | ― | 2.44% | -21.38% | 58.05% | |
69 Neutral | ¥5.79T | 12.87 | 10.61% | 3.26% | -8.02% | 5.21% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
61 Neutral | ¥2.06T | 17.25 | 8.83% | 2.74% | -1.96% | 10.32% |
Dai-ichi Life Holdings Corporate Events
Dai-ichi Life Holdings has entered into a capital and business alliance with Infomart Corporation and will acquire a significant minority stake through a combination of newly issued shares and disposal of treasury shares via third-party allotment. The transaction will give Dai-ichi Life 40,126,200 Infomart shares, equivalent to 15.06% of Infomart’s voting rights, and is structured as an act of buying up shares deemed equivalent to a tender offer under Japan’s Financial Instruments and Exchange Act.
The share acquisition, scheduled to close on March 2, 2026, underscores Dai-ichi Life’s use of strategic investments to deepen business collaboration and expand its influence beyond core insurance operations. By securing more than 5% of Infomart’s voting rights, the insurer strengthens its position as a long-term partner, potentially enhancing synergies between its financial services platform and Infomart’s business while signaling continued diversification of its investment portfolio.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings has approved the issuance of 6,000 new common shares as restricted stock compensation to executive officers and directors of the company and its group company Benefit One Inc. The program is part of an established stock remuneration scheme designed to align management’s interests with shareholders through direct share ownership and a defined transfer-restriction period.
The restricted stock scheme coexists with a performance-linked stock compensation plan, with the former positioned to promote profit-sharing with shareholders and the latter to incentivize improvement in corporate value. By refining the structure, including shorter transfer restrictions and claw-back provisions, the company aims to enhance governance and maintain an appropriate incentive framework for key executives within the group.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings will make an additional ¥7 billion contribution to its Japan Employee Stock Ownership Plan trust to fund the purchase of company shares for future employee stock grants. The trustee plans to acquire up to 7 million shares of Dai-ichi Life common stock on the market between February 25 and March 26, 2026, using the new funds and existing trust cash, a move already reflected in the company’s consolidated earnings forecast and signaling continued emphasis on employee equity-based compensation.
The additional J-ESOP funding underscores the company’s intent to maintain long-term incentive alignment between employees and shareholders through ongoing stock-based benefits. By supporting future share grants without immediate dilution beyond the planned market purchases, the program may bolster employee engagement and help strengthen corporate governance and performance orientation over time.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings has announced a major overhaul of its management structure, effective April 1, 2026, aimed at accelerating growth across its core businesses. The group will replace its current Protection (Japan) and Retirement, Saving and Asset Management business heads with two new roles: Business Head, Insurance (Japan), overseeing integrated strategy and management for domestic insurance operations, and Business Head, Asset Management, responsible for global asset management strategy and related businesses.
To support these new leadership roles, the company will create an Insurance Business Unit and an Asset Management Business Unit, reinforcing organizational alignment around its domestic insurance and global asset management domains. The restructuring is intended to sharpen strategic focus in key growth areas, streamline decision-making, and enhance unified management of Japanese insurance companies and worldwide investment activities, with implications for more coherent product development and operational oversight.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings has raised its consolidated earnings forecast for the fiscal year ending March 31, 2026, citing higher investment income at The Dai-ichi Frontier Life Insurance Co. and increased gains on sales of securities at The Dai-ichi Life Insurance Company driven by robust stock prices. The company now expects ordinary revenues of 11.067 trillion yen, ordinary profit of 718 billion yen, net income of 408 billion yen, and group adjusted profit of 500 billion yen, and is also lifting its year-end dividend forecast by 1 yen to 28 yen per share, signaling stronger profitability and enhanced shareholder returns.
These upward revisions indicate that favorable market conditions, particularly in equity markets, are supporting the group’s investment performance and capital generation capacity. The higher dividend outlook suggests management’s confidence in sustainable earnings and may improve the company’s attractiveness to income-focused investors, reinforcing its competitive position in Japan’s life insurance sector.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
The Neo First Life Insurance Company, a subsidiary of Dai-ichi Life Holdings, has disclosed its unaudited financial results for the nine months ended December 31, 2025, along with detailed supplementary materials. The release outlines business highlights, general account investment performance, balance sheet and earnings data, profit breakdowns, solvency margin information, separate account status, and a consolidated financial summary, providing stakeholders with an overview of the company’s interim financial health and risk capacity.
Although figures are not included in the announcement summary, the scope of the disclosed materials indicates a comprehensive interim reporting cycle typical for Japanese insurers. By publishing solvency margin ratios and investment results alongside core earnings metrics, Neo First Life aims to enhance transparency for regulators, investors, and policyholders, shedding light on its capital adequacy, profitability drivers, and the performance of both general and separate account assets within the Dai-ichi Life group structure.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
The Dai-ichi Frontier Life Insurance Co., Ltd., a core subsidiary of Dai-ichi Life Holdings, has released its financial results for the nine months ended December 31, 2025. The disclosure includes key materials such as business highlights, investment results, balance sheet data, earnings statements, solvency margin figures, and separate account status, offering investors a detailed view of the insurer’s interim performance.
While headline profit or revenue figures are not specified in the announcement, the breadth of disclosed materials signals a standard, comprehensive interim reporting cycle for the life insurer. This level of detail supports transparency for policyholders and shareholders, and provides insight into capital adequacy and investment performance ahead of the company’s full-year results.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Insurance, the main operating company of Dai-ichi Life Holdings, has released supplementary materials detailing its financial performance for the nine months ended December 31, 2025. The disclosure outlines business highlights, general account investment results, balance sheet and earnings data, solvency margin ratio, and separate account status for the period.
The company also provided a consolidated financial summary, indicating a comprehensive update on group-wide operations during the first three quarters of fiscal 2025. While specific figures were not included in the announcement text, the breadth of disclosed materials signals a routine but important progress report for investors and policyholders on profitability, capital soundness, and investment management.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings reported broadly stable top-line performance for the nine months ended December 31, 2025, with consolidated premium and other income edging down 0.3% to ¥5.09 trillion even as annualized net premiums of policies in force rose 7.8%, reflecting continued expansion in core protection business. Domestic units showed mixed trends, with Dai-ichi Life’s individual and group insurance premiums increasing and medical and survival benefits slightly declining, while Dai-ichi Frontier Life saw lower premium income but double-digit growth in annualized net premiums of new policies.
Overseas insurance operations were a key earnings driver, as group fundamental profit rose 5.0% to ¥455.6 billion, supported by a 32.0% jump in profits from overseas insurers, led by a 92.2% surge at U.S.-based Protective Life. Total assets grew 4.0% to ¥72.38 trillion and the solvency margin ratio improved to 672.1%, underscoring solid capital buffers even as adjusted net assets declined 9.5%, a mix that suggests the group remains financially resilient while shifting its profit base more heavily toward international businesses and higher-margin product segments.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings released outline materials summarizing its financial results for the nine months ended December 31, 2025, as part of its Q3 fiscal 2025 disclosure. The announcement signals the company’s ongoing commitment to regular, transparent financial reporting to investors and stakeholders, although detailed performance metrics and strategic implications were not disclosed in the text provided.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings reported consolidated ordinary revenues of ¥8.32 trillion for the nine months ended December 31, 2025, up 6.1% year-on-year, with ordinary profit rising 7.2% to ¥597.7 billion and net income attributable to shareholders increasing 4.7% to ¥370.3 billion. Total assets grew to ¥72.38 trillion and net assets attributable to shareholders improved to ¥4.08 trillion, while the company revised its full-year earnings and dividend forecasts, incorporating the impacts of its recent 1-for-4 share split and signaling sustained but moderating profit growth and shareholder returns.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1714.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings has reported the latest status of its ongoing share repurchase program, buying back 4,733,800 common shares for a total of about 6.45 billion yen on the open market between January 1 and January 31, 2026, via discretionary trading. This buyback is part of a broader board-approved program, authorized in May 2025, that allows repurchases of up to 200 million shares or 100 billion yen through March 31, 2026, under which the company has cumulatively repurchased 61,060,500 shares for approximately 71.96 billion yen as of January 31, 2026, signaling continued capital return to shareholders and active balance sheet management.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1562.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings has decided to expand its shareholder benefit program to align with its April 2025 stock split and to make its services more accessible to a wider base of retail investors. From the fiscal year ending March 31, 2026, shareholders residing in Japan who hold at least 100 shares, instead of the previous 400-share threshold, will become eligible for benefits, gaining access to the company’s ‘QOLism’ health-related point program and the ‘Benefit Station’ service. The company will also raise the maximum ‘QOLism’ points for shareholders holding 400 shares or more but fewer than 800 shares by the equivalent of ¥1,000, while benefits for those with 800 shares or more remain unchanged. By lowering the entry threshold and modestly enhancing mid-tier rewards, Dai-ichi Life aims to express appreciation to existing shareholders, promote usage of group services, and strengthen the appeal of holding its stock over the long term, potentially broadening its shareholder base and deepening engagement with individual investors.
The most recent analyst rating on (JP:8750) stock is a Buy with a Yen1391.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings has disclosed the latest status of its ongoing share repurchase program, reporting that it bought back 6,802,500 common shares on the open market between December 1 and December 31, 2025, at a total cost of approximately ¥8.49 billion using a discretionary trading method. This activity forms part of a broader board-approved buyback authorization from May 2025 permitting repurchases of up to 200 million shares or ¥100 billion through March 31, 2026; as of December 31, 2025, the company has cumulatively repurchased 56,326,700 shares for about ¥65.51 billion, signaling continued capital return to shareholders and potentially supporting earnings per share and capital efficiency as it manages its balance sheet and market valuation.
The most recent analyst rating on (JP:8750) stock is a Hold with a Yen1360.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings announced corrections to its previous notice regarding the repurchase of its shares. The correction involves the period of repurchase, which has been adjusted to end on March 31, 2026, instead of the initially stated May 31, 2026. This adjustment may impact the company’s financial strategies and shareholder relations.
The most recent analyst rating on (JP:8750) stock is a Hold with a Yen1360.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.
Dai-ichi Life Holdings announced the repurchase of 5,738,100 shares of its common stock, amounting to approximately 7 billion yen, conducted through open-market transactions in November 2025. This move is part of a broader repurchase plan approved in May 2025, aiming to buy back up to 200 million shares by March 2026, reflecting the company’s strategy to enhance shareholder value and optimize capital structure.
The most recent analyst rating on (JP:8750) stock is a Hold with a Yen1360.00 price target. To see the full list of analyst forecasts on Dai-ichi Life Holdings stock, see the JP:8750 Stock Forecast page.